Mechanisms of Cisplatin-Induced Acute Kidney Injury: Pathological Mechanisms, Pharmacological Interventions, and Genetic Mitigations
Open accessThe DOI matches its Crossref record; 271 of the 271 references it cites were found in a registry or an index.
Abstract
Administration of the chemotherapeutic agent cisplatin leads to acute kidney injury (AKI). Cisplatin-induced AKI (CIAKI) has a complex pathophysiological map, which has been linked to cellular uptake and efflux, apoptosis, vascular injury, oxidative and endoplasmic reticulum stress, and inflammation. Despite research efforts, pharmaceutical interventions, and clinical trials spanning over several decades, a consistent and stable pharmacological treatment option to reduce AKI in patients receiving cisplatin remains unavailable. This has been predominately linked to the incomplete understanding of CIAKI pathophysiology and molecular mechanisms involved. Herein, we detail the extensively known pathophysiology of cisplatin-induced nephrotoxicity that manifests and the variety of pharmacological and genetic alteration studies that target them.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pathogen Recognition and Innate Immunity
Akira, S., Uematsu, S., & Takeuchi, O. (2006) · Cell · doi:10.1016/j.cell.2006.02.015 · Cited by 11,952
Cisplatin in cancer therapy: Molecular mechanisms of action
Dasari, S., & Bernard Tchounwou, P. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.025 · Cited by 5,537
Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009
Kroemer, G., Galluzzi, L., Vandenabeele, P., Abrams, J., Alnemri, E. S., Baehrecke, E. H., Blagosklonny, M. V., El-Deiry, W. S., Golstein, P., Green, D. R., et al. (2009) · Cell Death & Differentiation · doi:10.1038/cdd.2008.150 · Cited by 3,399
Role of Adaptor TRIF in the MyD88-Independent Toll-Like Receptor Signaling Pathway
Yamamoto, M., Sato, S., Hemmi, H., Hoshino, K., Kaisho, T., Sanjo, H., Takeuchi, O., Sugiyama, M., Okabe, M., Takeda, K., et al. (2003) · Science · doi:10.1126/science.1087262 · Cited by 3,235
The pro- and anti-inflammatory properties of the cytokine interleukin-6
Scheller, J., Chalaris, A., Schmidt-Arras, D., & Rose-John, S. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.01.034 · Cited by 3,212 · cited 1×
“IL-6 is a pleiotropic cytokine predominantly exerting proinflammatory functions but also exhibits anti-inflammatory properties [279].”
BackgroundToll-like receptors in the induction of the innate immune response
Aderem, A., & Ulevitch, R. J. (2000) · Nature · doi:10.1038/35021228 · Cited by 3,064
Two CD95 (APO‐1/Fas) signaling pathways
Scaffidi, C., Fulda, S., Srinivasan, A., Friesen, C., Li, F., Tomaselli, K. J., Debatin, K., Krammer, P. H., & Peter, M. E. (1998) · The EMBO Journal · doi:10.1093/emboj/17.6.1675 · Cited by 3,000
Bellomo, R., Kellum, J. A., & Ronco, C. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61454-2 · Cited by 2,598
Galluzzi, L., Vitale, I., Abrams, J. M., Alnemri, E. S., Baehrecke, E. H., Blagosklonny, M. V., Dawson, T. M., Dawson, V. L., El-Deiry, W. S., Fulda, S., et al. (2012) · Cell Death & Differentiation · doi:10.1038/cdd.2011.96 · Cited by 2,421
Molecular mechanisms of necroptosis: an ordered cellular explosion
Vandenabeele, P., Galluzzi, L., Vanden Berghe, T., & Kroemer, G. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2970 · Cited by 2,382 · cited 1×
“Necrosis was considered as accidental cell death, which is unregulated [144] until genetic programmed necrosis was discovered in vivo [145,146].”
BackgroundCellular pathophysiology of ischemic acute kidney injury
Bonventre, J. V., & Yang, L. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45161 · Cited by 2,019
RIP3, an Energy Metabolism Regulator That Switches TNF-Induced Cell Death from Apoptosis to Necrosis
Zhang, D.-W., Shao, J., Lin, J., Zhang, N., Lu, B.-J., Lin, S.-C., Dong, M.-Q., & Han, J. (2009) · Science · doi:10.1126/science.1172308 · Cited by 1,931 · cited 1×
“Necrosis was considered as accidental cell death, which is unregulated [144] until genetic programmed necrosis was discovered in vivo [145,146].”
BackgroundCisplatin nephrotoxicity: Mechanisms and renoprotective strategies
Pabla, N., & Dong, Z. (2008) · Kidney International · doi:10.1038/sj.ki.5002786 · Cited by 1,918
Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus
Kurt-Jones, E. A., Popova, L., Kwinn, L., Haynes, L. M., Jones, L. P., Tripp, R. A., Walsh, E. E., Freeman, M. W., Golenbock, D. T., Anderson, L. J., et al. (2000) · Nature Immunology · doi:10.1038/80833 · Cited by 1,683
Mechanisms of Cisplatin Nephrotoxicity
Miller, R. P., Tadagavadi, R. K., Ramesh, G., & Reeves, W. B. (2010) · Toxins · doi:10.3390/toxins2112490 · Cited by 1,622
EINHORN, L. H., & DONOHUE, J. (1977) · Annals of Internal Medicine · doi:10.7326/0003-4819-87-3-293 · Cited by 1,545
Death by design: apoptosis, necrosis and autophagy
Edinger, A. L., & Thompson, C. B. (2004) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2004.09.011 · Cited by 1,364
Zarember, K. A., & Godowski, P. J. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.2.554 · Cited by 1,250
Recognition of lipopolysaccharide pattern by TLR4 complexes
Park, B. S., & Lee, J.-O. (2013) · Experimental & Molecular Medicine · doi:10.1038/emm.2013.97 · Cited by 1,234
Neural control of renal function
DiBona, G. F., & Kopp, U. C. (1997) · Physiological Reviews · doi:10.1152/physrev.1997.77.1.75 · Cited by 1,212
Neural Control of Renal Function*
Kopp, U. C., & DiBona, G. F. (2020) · Reflex Control of the Circulation · doi:10.1201/9780367813338-17 · Cited by 1,126
Green, D. R., & Llambi, F. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a006080 · Cited by 1,101
Howard, S. C., Jones, D. P., & Pui, C.-H. (2011) · New England Journal of Medicine · doi:10.1056/nejmra0904569 · Cited by 1,044
A Toll-like Receptor That Prevents Infection by Uropathogenic Bacteria
Zhang, D., Zhang, G., Hayden, M. S., Greenblatt, M. B., Bussey, C., Flavell, R. A., & Ghosh, S. (2004) · Science · doi:10.1126/science.1094351 · Cited by 1,004
DAMPening Inflammation by Modulating TLR Signalling
Piccinini, A. M., & Midwood, K. S. (2010) · Mediators of Inflammation · doi:10.1155/2010/672395 · Cited by 973
Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals
Ishida, S., Lee, J., Thiele, D. J., & Herskowitz, I. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162491399 · Cited by 927
TNF-α mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity
Ramesh, G., & Reeves, W. B. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15606 · Cited by 866
Classification of cell death: recommendations of the Nomenclature Committee on Cell Death
Kroemer, G., El-Deiry, W. S., Golstein, P., Peter, M. E., Vaux, D., Vandenabeele, P., Zhivotovsky, B., Blagosklonny, M. V., Malorni, W., Knight, R. A., et al. (2005) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401724 · Cited by 843
The Role of TLR2 in Infection and Immunity
Oliveira-Nascimento, L., Massari, P., & Wetzler, L. M. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00079 · Cited by 824
Autophagy: assays and artifacts
Barth, S., Glick, D., & Macleod, K. F. (2010) · The Journal of Pathology · doi:10.1002/path.2694 · Cited by 793
Leucine-rich repeats and pathogen recognition in Toll-like receptors
Bell, J. K., Mullen, G. E. D., Leifer, C. A., Mazzoni, A., Davies, D. R., & Segal, D. M. (2003) · Trends in Immunology · doi:10.1016/s1471-4906(03)00242-4 · Cited by 762
Tumor necrosis factor and cancer, buddies or foes?
Wang, X., & Lin, Y. (2008) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2008.00889.x · Cited by 730
Pathophysiology of Cisplatin-Induced Acute Kidney Injury
Ozkok, A., & Edelstein, C. L. (2014) · BioMed Research International · doi:10.1155/2014/967826 · Cited by 703
The evolution and genetics of innate immunity
Kimbrell, D. A., & Beutler, B. (2001) · Nature Reviews Genetics · doi:10.1038/35066006 · Cited by 679
Cisplatin nephrotoxicity: a review of the literature
Manohar, S., & Leung, N. (2018) · Journal of Nephrology · doi:10.1007/s40620-017-0392-z · Cited by 636
Wang, M., Wey, S., Zhang, Y., Ye, R., & Lee, A. S. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2485 · Cited by 609
Baeck, C., Wehr, A., Karlmark, K. R., Heymann, F., Vucur, M., Gassler, N., Huss, S., Klussmann, S., Eulberg, D., Luedde, T., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-300304 · Cited by 609
Chemokines and Chemokine Receptors: New Targets for Cancer Immunotherapy
Mollica Poeta, V., Massara, M., Capucetti, A., & Bonecchi, R. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00379 · Cited by 583
Mechanisms of cisplatin-induced ototoxicity and prevention
Rybak, L. P., Whitworth, C. A., Mukherjea, D., & Ramkumar, V. (2007) · Hearing Research · doi:10.1016/j.heares.2006.09.015 · Cited by 563
Linkermann, A., Chen, G., Dong, G., Kunzendorf, U., Krautwald, S., & Dong, Z. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014030262 · Cited by 563
Renal-associated TLR2 mediates ischemia/reperfusion injury in the kidney
Leemans, J. C., Stokman, G., Claessen, N., Rouschop, K. M., Teske, G. J. D., Kirschning, C. J., Akira, S., van der Poll, T., Weening, J. J., & Florquin, S. (2005) · Journal of Clinical Investigation · doi:10.1172/jci22832 · Cited by 563
Sampaio, W. O., Souza dos Santos, R. A., Faria-Silva, R., da Mata Machado, L. T., Schiffrin, E. L., & Touyz, R. M. (2007) · Hypertension · doi:10.1161/01.hyp.0000251865.35728.2f · Cited by 562
Cisplatin Induces Endoplasmic Reticulum Stress and Nucleus-independent Apoptotic Signaling
Mandic, A., Hansson, J., Linder, S., & Shoshan, M. C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210284200 · Cited by 509
Involvement of Toll-Like Receptor 4 in Innate Immunity to Respiratory Syncytial Virus
Haynes, L. M., Moore, D. D., Kurt-Jones, E. A., Finberg, R. W., Anderson, L. J., & Tripp, R. A. (2001) · Journal of Virology · doi:10.1128/jvi.75.22.10730-10737.2001 · Cited by 496
Role of oxidative and nitrosative stress in cisplatin-induced nephrotoxicity
Chirino, Y. I., & Pedraza-Chaverri, J. (2009) · Experimental and Toxicologic Pathology · doi:10.1016/j.etp.2008.09.003 · Cited by 489
Cisplatin nephrotoxicity: molecular mechanisms.
Hanigan, M. H., & Devarajan, P. (2003) · PubMed · Cited by 476
CHOP is a multifunctional transcription factor in the ER stress response
Nishitoh, H. (2012) · Journal of Biochemistry · doi:10.1093/jb/mvr143 · Cited by 469
Kemp, G., Rose, P., Lurain, J., Berman, M., Manetta, A., Roullet, B., Homesley, H., Belpomme, D., & Glick, J. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.7.2101 · Cited by 463
Cisplatin Nephrotoxicity Is Critically Mediated via the Human Organic Cation Transporter 2
Ciarimboli, G., Ludwig, T., Lang, D., Pavenstädt, H., Koepsell, H., Piechota, H.-J., Haier, J., Jaehde, U., Zisowsky, J., & Schlatter, E. (2005) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61234-5 · Cited by 448
Ciarimboli, G., Deuster, D., Knief, A., Sperling, M., Holtkamp, M., Edemir, B., Pavenstädt, H., Lanvers-Kaminsky, C., am Zehnhoff-Dinnesen, A., Schinkel, A. H., et al. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.090610 · Cited by 444
Volarevic, V., Djokovic, B., Jankovic, M. G., Harrell, C. R., Fellabaum, C., Djonov, V., & Arsenijevic, N. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-019-0518-9 · Cited by 438
Gao, J., Nutter, J., Liu, X., Guan, D., Huang, Y., Dye, D., & Rainforth, W. M. (2018) · Scientific Reports · doi:10.1038/s41598-018-25899-3 · Cited by 426
Vascular Endothelial Function and Hypertension: Insights and Directions
Dharmashankar, K., & Widlansky, M. E. (2010) · Current Hypertension Reports · doi:10.1007/s11906-010-0150-2 · Cited by 424
Bcl-2 prevents apoptotic mitochondrial dysfunction by regulating proton flux
Shimizu, S., Eguchi, Y., Kamiike, W., Funahashi, Y., Mignon, A., Lacronique, V., Matsuda, H., & Tsujimoto, Y. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.4.1455 · Cited by 410
Interleukin-10 inhibits ischemic and cisplatin-induced acute renal injury
Deng, J., Kohda, Y., Chiao, H., Wang, Y., Hu, X., Hewitt, S. M., Miyaji, T., Mcleroy, P., Nibhanupudy, B., Li, S., et al. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00043.x · Cited by 399
Faubel, S., Lewis, E. C., Reznikov, L., Ljubanovic, D., Hoke, T. S., Somerset, H., Oh, D.-J., Lu, L., Klein, C. L., Dinarello, C. A., et al. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.119792 · Cited by 399
Comparative sequence analysis of leucine-rich repeats (LRRs) within vertebrate toll-like receptors
Matsushima, N., Tanaka, T., Enkhbayar, P., Mikami, T., Taga, M., Yamada, K., & Kuroki, Y. (2007) · BMC Genomics · doi:10.1186/1471-2164-8-124 · Cited by 393
Use of rodents as models of human diseases
Vandamme, T. (2014) · Journal of Pharmacy And Bioallied Sciences · doi:10.4103/0975-7406.124301 · Cited by 389
Toll-Like Receptor 4 Promotes Tubular Inflammation in Diabetic Nephropathy
Lin, M., Yiu, W. H., Wu, H. J., Chan, L. Y. Y., Leung, J. C. K., Au, W. S., Chan, K. W., Lai, K. N., & Tang, S. C. W. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010111210 · Cited by 386
Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update
dos Santos, N. A. G., Carvalho Rodrigues, M. A., Martins, N. M., & dos Santos, A. C. (2012) · Archives of Toxicology · doi:10.1007/s00204-012-0821-7 · Cited by 378
Holditch, S. J., Brown, C. N., Lombardi, A. M., Nguyen, K. N., & Edelstein, C. L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20123011 · Cited by 377
Cisplatin Ototoxicity and Protection: Clinical and Experimental Studies
Rybak, L. P., Mukherjea, D., Jajoo, S., & Ramkumar, V. (2009) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.219.177 · Cited by 372
Tumour necrosis factor α: a potential target for the therapy of solid tumours
Szlosarek, P. W., & Balkwill, F. R. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01196-3 · Cited by 355
A Role for Tubular Necroptosis in Cisplatin-Induced AKI
Xu, Y., Ma, H., Shao, J., Wu, J., Zhou, L., Zhang, Z., Wang, Y., Huang, Z., Ren, J., Liu, S., et al. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014080741 · Cited by 354
Bagchi, A., Herrup, E. A., Warren, H. S., Trigilio, J., Shin, H.-S., Valentine, C., & Hellman, J. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.2.1164 · Cited by 347
Yonezawa, A., Masuda, S., Yokoo, S., Katsura, T., & Inui, K.-I. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.110346 · Cited by 344
Chemokine CXCL1 mediated neutrophil recruitment: Role of glycosaminoglycan interactions
Sawant, K. V., Poluri, K. M., Dutta, A. K., Sepuru, K. M., Troshkina, A., Garofalo, R. P., & Rajarathnam, K. (2016) · Scientific Reports · doi:10.1038/srep33123 · Cited by 337 · cited 2×
“The molecular structure of CXCL1 can be either a monomer or a dimer and is a highly potent CXCR2 receptor agonist [292].”
BackgroundCopper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance.
Komatsu, M., Sumizawa, T., Mutoh, M., Chen, Z., Terada, K., Furukawa, T., Yang, X., Gao, H., Miura, N., Sugiyama, T., et al. (2000) · PubMed · Cited by 328
Farhat, K., Riekenberg, S., Heine, H., Debarry, J., Lang, R., Mages, J., Buwitt-Beckmann, U., Röschmann, K., Jung, G., Wiesmüller, K.-H., et al. (2008) · Journal of Leukocyte Biology · doi:10.1189/jlb.0807586 · Cited by 321
Metabolism of Cisplatin to a Nephrotoxin in Proximal Tubule Cells
Townsend, D. M., Deng, M., Zhang, L., Lapus, M. G., & Hanigan, M. H. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000042803.28024.92 · Cited by 317
TLR4 Signaling Mediates Inflammation and Tissue Injury in Nephrotoxicity
Zhang, B., Ramesh, G., Uematsu, S., Akira, S., & Reeves, W. B. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007090982 · Cited by 317
Animal to human translation: a systematic scoping review of reported concordance rates
Leenaars, C. H. C., Kouwenaar, C., Stafleu, F. R., Bleich, A., Ritskes-Hoitinga, M., De Vries, R. B. M., & Meijboom, F. L. B. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1976-2 · Cited by 314 · cited 2×
“Reproducibility in both animal and human studies has also posed an issue regarding translatability [296].”
BackgroundZhang, B., Ramesh, G., Norbury, C. C., & Reeves, W. B. (2007) · Kidney International · doi:10.1038/sj.ki.5002242 · Cited by 309
Regulation of the autophagy protein LC3 by phosphorylation
Cherra, S. J., Kulich, S. M., Uechi, G., Balasubramani, M., Mountzouris, J., Day, B. W., & Chu, C. T. (2010) · Journal of Cell Biology · doi:10.1083/jcb.201002108 · Cited by 304
Thomas, P. G., Carter, M. R., Atochina, O., Da’Dara, A. A., Piskorska, D., McGuire, E., & Harn, D. A. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.11.5837 · Cited by 300
Mihaly, S. R., Ninomiya-Tsuji, J., & Morioka, S. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2014.123 · Cited by 288
Pabla, N., Murphy, R. F., Liu, K., & Dong, Z. (2009) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.90545.2008 · Cited by 283
The roles of copper transporters in cisplatin resistance
Kuo, M. T., Chen, H. H. W., Song, I.-S., Savaraj, N., & Ishikawa, T. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9045-3 · Cited by 283
A Molecular Mechanism for Direct Sirtuin Activation by Resveratrol
Gertz, M., Nguyen, G. T. T., Fischer, F., Suenkel, B., Schlicker, C., Fränzel, B., Tomaschewski, J., Aladini, F., Becker, C., Wolters, D., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049761 · Cited by 283
Shigeoka, A. A., Holscher, T. D., King, A. J., Hall, F. W., Kiosses, W. B., Tobias, P. S., Mackman, N., & McKay, D. B. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.10.6252 · Cited by 273
VDR activation attenuate cisplatin induced AKI by inhibiting ferroptosis
Hu, Z., Zhang, H., Yi, B., Yang, S., Liu, J., Hu, J., Wang, J., Cao, K., & Zhang, W. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-2256-z · Cited by 271
p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice
Ramesh, G., & Reeves, W. B. (2005) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00401.2004 · Cited by 267
Nitric Oxide Modulates Superoxide Release and Peroxynitrite Formation in Human Blood Vessels
Guzik, T. J., West, N. E. J., Pillai, R., Taggart, D. P., & Channon, K. M. (2002) · Hypertension · doi:10.1161/01.hyp.0000018041.48432.b5 · Cited by 264
Improvement of Cis-dichlorodiammineplatinum (NSC 119875): Therapeutic index in an animal model
Cvitkovic, E., Spaulding, J., Bethune, V., Martin, J., & Whitmore, W. F. (1977) · Cancer · doi:10.1002/1097-0142(197704)39:4<1357::aid-cncr2820390402>3.0.co;2-c · Cited by 259
SEVERE NEUROTOXICITY, OTOTOXICITY AND NEPHROTOXICITY FOLLOWING HIGH-DOSE CISPLATIN AND AMIFOSTINE
Sastry, J., & Kellie, S. J. (2005) · Pediatric Hematology and Oncology · doi:10.1080/08880010590964381 · Cited by 258
Autophagy Guards Against Cisplatin-Induced Acute Kidney Injury
Takahashi, A., Kimura, T., Takabatake, Y., Namba, T., Kaimori, J., Kitamura, H., Matsui, I., Niimura, F., Matsusaka, T., Fujita, N., et al. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.11.001 · Cited by 253
Human TLRs 10 and 1 Share Common Mechanisms of Innate Immune Sensing but Not Signaling
Guan, Y., Ranoa, D. R. E., Jiang, S., Mutha, S. K., Li, X., Baudry, J., & Tapping, R. I. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0901888 · Cited by 251
Chen, X., Wei, W., Li, Y., Huang, J., & Ci, X. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.05.040 · Cited by 250
Takashima, K., Matsunaga, N., Yoshimatsu, M., Hazeki, K., Kaisho, T., Uekata, M., Hazeki, O., Akira, S., Iizawa, Y., & Ii, M. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00297.x · Cited by 246
Kropf, P., Freudenberg, M. A., Modolell, M., Price, H. P., Herath, S., Antoniazi, S., Galanos, C., Smith, D. F., & Müller, I. (2004) · Infection and Immunity · doi:10.1128/iai.72.4.1920-1928.2004 · Cited by 243
Tsuruya, K., Ninomiya, T., Tokumoto, M., Hirakawa, M., Masutani, K., Taniguchi, M., Fukuda, K., Kanai, H., Kishihara, K., Hirakata, H., et al. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00709.x · Cited by 241
Cisplatin-induced Kidney Dysfunction and Perspectives on Improving Treatment Strategies
Oh, G.-S., Kim, H.-J., Shen, A., Lee, S. B., Khadka, D., Pandit, A., & So, H.-S. (2014) · Electrolytes & Blood Pressure · doi:10.5049/ebp.2014.12.2.55 · Cited by 239
The Copper Transporter CTR1 Regulates Cisplatin Uptake in Saccharomyces cerevisiae
Lin, X., Okuda, T., Holzer, A., & Howell, S. B. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.5.1154 · Cited by 232
Toll-Like Receptor 4 Expression and Cytokine Responses in the Human Urinary Tract Mucosa
Samuelsson, P., Hang, L., Wullt, B., Irjala, H., & Svanborg, C. (2004) · Infection and Immunity · doi:10.1128/iai.72.6.3179-3186.2004 · Cited by 228
Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity
Nakamura, T., Yonezawa, A., Hashimoto, S., Katsura, T., & Inui, K.-I. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.08.019 · Cited by 221
Toll‐like receptor 9 signaling protects against murine lupus
Wu, X., & Peng, S. L. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21553 · Cited by 220
Kellum, J. A. (2008) · Critical Care Medicine · doi:10.1097/ccm.0b013e318168c4a4 · Cited by 211
Regulation of PUMA-α by p53 in cisplatin-induced renal cell apoptosis
Jiang, M., Wei, Q., Wang, J., Du, Q., Yu, J., Zhang, L., & Dong, Z. (2006) · Oncogene · doi:10.1038/sj.onc.1209440 · Cited by 209
Acute kidney injury: a guide to diagnosis and management.
Rahman, M., Shad, F., & Smith, M. C. (2012) · PubMed · Cited by 203
Dynamics of the Degradation of Ubiquitinated Proteins by Proteasomes and Autophagy
Myeku, N., & Figueiredo-Pereira, M. E. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.149252 · Cited by 203
Danger-Associated Molecular Patterns (DAMPs): the Derivatives and Triggers of Inflammation
Patel, S. (2018) · Current Allergy and Asthma Reports · doi:10.1007/s11882-018-0817-3 · Cited by 197
Cytokines in cancer drug resistance: Cues to new therapeutic strategies
Jones, V. S., Huang, R.-Y., Chen, L.-P., Chen, Z.-S., Fu, L., & Huang, R.-P. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.03.005 · Cited by 195
Endoplasmic Reticulum Stress–Associated Caspase 12 Mediates Cisplatin-Induced LLC-PK1 Cell Apoptosis
Liu, H., & Baliga, R. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004090768 · Cited by 182
Gómez-Ruiz, S., Maksimović-Ivanić, D., Mijatović, S., & Kaluđerović, G. N. (2012) · Bioinorganic Chemistry and Applications · doi:10.1155/2012/140284 · Cited by 182
A Pathophysiologic Role for T Lymphocytes in Murine Acute Cisplatin Nephrotoxicity
Liu, M., Chien, C.-C., Burne-Taney, M., Molls, R. R., Racusen, L. C., Colvin, R. B., & Rabb, H. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005010102 · Cited by 182
tenOever, B. R., Sharma, S., Zou, W., Sun, Q., Grandvaux, N., Julkunen, I., Hemmi, H., Yamamoto, M., Akira, S., Yeh, W.-C., et al. (2004) · Journal of Virology · doi:10.1128/jvi.78.19.10636-10649.2004 · Cited by 181
Endoplasmic reticulum stress as a progression factor for kidney injury
Inagi, R. (2010) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2009.11.006 · Cited by 179
Turning point in apoptosis/necrosis induced by hydrogen peroxide
Saito, Y., Nishio, K., Ogawa, Y., Kimata, J., Kinumi, T., Yoshida, Y., Noguchi, N., & Niki, E. (2006) · Free Radical Research · doi:10.1080/10715760600632552 · Cited by 178
Endoplasmic reticulum stress in ischemic and nephrotoxic acute kidney injury
Yan, M., Shu, S., Guo, C., Tang, C., & Dong, Z. (2018) · Annals of Medicine · doi:10.1080/07853890.2018.1489142 · Cited by 177
Urry, Z., Xystrakis, E., Richards, D. F., McDonald, J., Sattar, Z., Cousins, D. J., Corrigan, C. J., Hickman, E., Brown, Z., & Hawrylowicz, C. M. (2009) · Journal of Clinical Investigation · doi:10.1172/jci32354 · Cited by 176
CXCL16 Is a Marker of Inflammation, Atherosclerosis, and Acute Coronary Syndromes in Humans
Lehrke, M., Millington, S. C., Lefterova, M., Cumaranatunge, R. G., Szapary, P., Wilensky, R., Rader, D. J., Lazar, M. A., & Reilly, M. P. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.09.034 · Cited by 173
Tan, Y., Zanoni, I., Cullen, T. W., Goodman, A. L., & Kagan, J. C. (2015) · Immunity · doi:10.1016/j.immuni.2015.10.008 · Cited by 173
Liu, H., & Baliga, R. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00908.x · Cited by 171
Shenoy, V., Gjymishka, A., Jarajapu, Y. P., Qi, Y., Afzal, A., Rigatto, K., Ferreira, A. J., Fraga-Silva, R. A., Kearns, P., Douglas, J. Y., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201205-0880oc · Cited by 167
Mäkelä, S. M., Strengell, M., Pietilä, T. E., Österlund, P., & Julkunen, I. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.0808503 · Cited by 167
Zhang, C., Hein, T. W., Wang, W., & Kuo, L. (2003) · Circulation Research · doi:10.1161/01.res.0000056759.53828.2c · Cited by 165
Backhed, F., Soderhall, M., Ekman, P., Normark, S., & Richter-Dahlfors, A. (2001) · Cellular Microbiology · doi:10.1046/j.1462-5822.2001.00101.x · Cited by 164
IL-33 Exacerbates Acute Kidney Injury
Akcay, A., Nguyen, Q., He, Z., Turkmen, K., Won Lee, D., Hernando, A. A., Altmann, C., Toker, A., Pacic, A., Ljubanovic, D. G., et al. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010091011 · Cited by 163
Relevance of Toll-like receptor-4 polymorphisms in renal transplantation
Ducloux, D., Deschamps, M., Yannaraki, M., Ferrand, C., Bamoulid, J., Saas, P., Kazory, A., Chalopin, J.-M., & Tiberghien, P. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00354.x · Cited by 162
Chemotherapy advances in small-cell lung cancer.
Chan, B. A., & Coward, J. I. G. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2013.07.43 · Cited by 155
Novel Role of Toll-Like Receptor 3 in Hepatitis C-Associated Glomerulonephritis
Wörnle, M., Schmid, H., Banas, B., Merkle, M., Henger, A., von Roeder, M., Blattner, S. M., Bock, E., Kretzler, M., Gröne, H., et al. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.050491 · Cited by 152
Kim, H. J., Lee, D. W., Ravichandran, K., Keys, D. O., Akçay, A., Nguyen, Q., He, Z., Jani, A. H., Ljubanović, D. G., & Edelstein, C. L. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.205732 · Cited by 143
Membrane transporters as mediators of cisplatin side-effects.
Ciarimboli, G. (2014) · PubMed · Cited by 141
Peyrou, M., Hanna, P. E., & Cribb, A. E. (2007) · Toxicological Sciences · doi:10.1093/toxsci/kfm152 · Cited by 141
Samimi, G., Varki, N. M., Wilczynski, S. P., Safaei, R., Alberts, D. S., & Howell, S. B. (2003) · PubMed · Cited by 139
Wang, Y., Abel, K., Lantz, K., Krieg, A. Μ., McChesney, M. B., & Miller, C. J. (2005) · Journal of Virology · doi:10.1128/jvi.79.22.14355-14370.2005 · Cited by 139
Zhang, Y., He, X., Feng, Y. Y., Xiang, Z., Li, J., Thorpe, K. L., & Yu, Z. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076464 · Cited by 135
Pedersen, G., Andresen, L., Matthiessen, M. W., Rask-Madsen, J., & Brynskov, J. (2005) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2005.02848.x · Cited by 135
Butcher, S., O’Carroll, C., Wells, C. A., & Carmody, R. J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00933 · Cited by 131
Role of glutathione S-transferase Pi in cisplatin-induced nephrotoxicity
Townsend, D. M., Tew, K. D., He, L., King, J. B., & Hanigan, M. H. (2008) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2008.08.004 · Cited by 130
Lameire, N. H., Biesen, W. V., & Vanholder, R. C. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61794-8 · Cited by 129
Rachmawati, D., Bontkes, H. J., Verstege, M. I., Muris, J., Blomberg, B. M. E. V., Scheper, R. J., & van Hoogstraten, I. M. W. (2013) · Contact Dermatitis · doi:10.1111/cod.12042 · Cited by 126
Cao, Z., Bonnet, F., Candido, R., Nesteroff, S. P., Burns, W. C., Kawachi, H., Shimizu, F., Carey, R. M., de Gasparo, M., & Cooper, M. E. (2002) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000019409.17099.33 · Cited by 126
The Role of Toll-Like Receptors in the Production of Cytokines by Human Lung Macrophages
Grassin‐Delyle, S., Abrial, C., Salvator, H., Brollo, M., Naline, E., & Devillier, P. (2018) · Journal of Innate Immunity · doi:10.1159/000494463 · Cited by 125
Tan, R., Wang, C., Deng, C., Zhong, X., Yan, Y., Luo, Y., Lan, H., He, T., & Wang, L. (2019) · Phytotherapy Research · doi:10.1002/ptr.6507 · Cited by 125
NF-κB transcriptional inhibition ameliorates cisplatin-induced acute kidney injury (AKI)
Özkök, A., Ravichandran, K., Wang, Q., Ljubanović, D. G., & Edelstein, C. L. (2015) · Toxicology Letters · doi:10.1016/j.toxlet.2015.10.028 · Cited by 122
Szturz, P., Wouters, K., Kiyota, N., Tahara, M., Prabhash, K., Noronha, V., Adelstein, D. J., Gestel, D. V., & Vermorken, J. B. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00086 · Cited by 122
The anticancer drug cisplatin induces an intrinsic apoptotic pathway inside the inner ear
García‐Berrocal, J. R., Nevado, J. B., Ramírez‐Camacho, R., Fernández, R. S., González-García, J. Á., Sánchez‐Rodríguez, C., Cantos, B., España, P., Verdaguer, J. M., & Cabezas, A. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707405 · Cited by 121
Kalayda, G. V., Wagner, C. H., Buß, I., Reedijk, J., & Jaehde, U. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-175 · Cited by 120
Molecular Biology and Physiology of Volume-Regulated Anion Channel (VRAC)
Osei‐Owusu, J., Yang, J., Vitery, M. D. C., & Qiu, Z. (2018) · Current topics in membranes · doi:10.1016/bs.ctm.2018.07.005 · Cited by 120
Mallavia, B., Liu, F., Lefrançais, E., Cleary, S. J., Kwaan, N., Tian, J. J., Magnen, M., Sayah, D. M., Soong, A., Chen, J., et al. (2019) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2019-0140oc · Cited by 119
Lu, L., Oh, D., Dursun, B., He, Z., Hoke, T. S., Faubel, S. G., & Edelstein, C. L. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.130161 · Cited by 117
Regulation of vascular smooth muscle tone
Walsh, M. P. (1994) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y94-130 · Cited by 117
Malik, S., Suchal, K., Gamad, N., Dinda, A. K., Arya, D. S., & Bhatia, J. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.12.008 · Cited by 116
Role of transporters in the distribution of platinum-based drugs
Harrach, S., & Ciarimboli, G. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00085 · Cited by 114
Yamada, M., Ichikawa, T., Ii, M., Sunamoto, M., Itoh, K., Tamura, N., & Kitazaki, T. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050623t · Cited by 112
Furuichi, K., Kaneko, S., & Wada, T. (2008) · Clinical and Experimental Nephrology · doi:10.1007/s10157-008-0119-5 · Cited by 111
Dependence of Cisplatin-Induced Cell Death In Vitro and In Vivo on Cyclin-Dependent Kinase 2
Price, P. M., Yu, F. Z., Kaldis, P., Aleem, E. A., Nowak, G. D. A., Safirstein, R. L., & Megyesi, J. K. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006020162 · Cited by 111
Angiotensin II Blockade and Renal Protection
Kobori, H., Mori, H., Masaki, T., & Nishiyama, A. (2013) · Current Pharmaceutical Design · doi:10.2174/1381612811319170009 · Cited by 110
Gupta, S., & Wright, H. M. (2008) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2008.00054.x · Cited by 107
Adverse Renal Effects of Novel Molecular Oncologic Targeted Therapies: A Narrative Review
Jhaveri, K. D., Wanchoo, R., Sakhiya, V., Ross, D. W., & Fishbane, S. N. (2016) · Kidney International Reports · doi:10.1016/j.ekir.2016.09.055 · Cited by 106
Membrane Transporters as Mediators of Cisplatin Effects and Side Effects
Ciarimboli, G. (2012) · Scientifica · doi:10.6064/2012/473829 · Cited by 105
Mi, X.-J., Hou, J., Wang, Z., Han, Y., Ren, S., Hu, J., Chen, C., & Li, W. (2018) · Scientific Reports · doi:10.1038/s41598-018-34156-6 · Cited by 105
Zhang, K., & Kaufman, R. J. (2008) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(08)01420-1 · Cited by 104
Endogenous IL-10 Attenuates Cisplatin Nephrotoxicity: Role of Dendritic Cells
Tadagavadi, R. K., & Reeves, W. B. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000383 · Cited by 103
Verzola, D., Cappuccino, L., D’Amato, E., Villaggio, B., Gianiorio, F., Mij, M., Simonato, A., Viazzi, F. C., Salvidio, G., & Garibotto, G. (2014) · Kidney International · doi:10.1038/ki.2014.116 · Cited by 101
Dennen, P., Altmann, C. J., Kaufman, J. L., Klein, C. L., Andrés-Hernando, A., Ahuja, N. H., Edelstein, C. L., Cadnapaphornchai, M. A., Keniston, A., & Faubel, S. G. (2010) · Critical Care · doi:10.1186/cc9289 · Cited by 101
Cisplatin-induced oxidative stress stimulates renal Fas ligand shedding
Soni, H., Kaminski, D., Gangaraju, R., & Adebiyi, A. (2018) · Renal Failure · doi:10.1080/0886022x.2018.1456938 · Cited by 101
Xing, J., Hou, J., Ma, Z., Wang, Z., Ren, S., Wang, Y., Liu, W., Chen, C., & Li, W. (2019) · Cell Proliferation · doi:10.1111/cpr.12627 · Cited by 101
Poly(ADP-ribose) polymerase-1 is a key mediator of cisplatin-induced kidney inflammation and injury
Mukhopadhyay, P., Horváth, B., Kechrid, M., Tanchian, G., Rajesh, M., Naura, A. S., Boulares, A. H., & Pacher, P. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.08.006 · Cited by 99
Sinapic acid modulates Nrf2/HO-1 signaling pathway in cisplatin-induced nephrotoxicity in rats
Ansari, M. A. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.06.085 · Cited by 96
Li, Q., Guo, D., Dong, Z., Zhang, W., Zhang, L., Huang, S. M., Polli, J. E., & Shu, Y. (2013) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2013.08.024 · Cited by 91
González‐Guerrero, C., Cannata‐Ortiz, P., Guerri, C., Egido, J., Ortíz, A., & Ramos, A. M. (2016) · Archives of Toxicology · doi:10.1007/s00204-016-1830-8 · Cited by 91
APX-115, a first-in-class pan-NADPH oxidase (Nox) inhibitor, protects db/db mice from renal injury
Joo, J., Min, H. S., Kim, K., Kim, J. E., Ghee, J. Y., Kim, H. W., Lee, J. E., Han, J., Lee, G.-Y., Ha, H., et al. (2017) · Laboratory Investigation · doi:10.1038/labinvest.2017.2 · Cited by 91
Cisplatin-induced renal inflammation is ameliorated by cilastatin nephroprotection
Humanes, B., Camaño, S., de Lara, J. M. T., Sabisetti, V. S., González-Nicolás, M. Á., Bonventre, J. V., Tejedor, A., & Lázaro, A. (2017) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfx005 · Cited by 90
Dhande, I. S., Ma, W., & Hussain, T. (2014) · Hypertension Research · doi:10.1038/hr.2014.132 · Cited by 89
Acute kidney injury in the patient with cancer
Rosner, M. H., & Perazella, M. A. (2019) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.19.042 · Cited by 88
Dhande, I. S., Ali, Q., & Hussain, T. (2013) · Hypertension · doi:10.1161/hypertensionaha.111.00422 · Cited by 87
Isolated Toll-like Receptor Transmembrane Domains Are Capable of Oligomerization
Godfroy, J. I., Roostan, M., Moroz, Y. S., Korendovych, I. V., & Yin, H. H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048875 · Cited by 87
Liu, P., Li, X., Lv, W., & Xu, Z. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109693 · Cited by 87
Wehr, A., Baeck, C., Ulmer, T. F., Gaßler, N., Hittatiya, K., Luedde, T., Neumann, U. P., Trautwein, C., & Tacke, F. (2014) · PLoS ONE · doi:10.1371/journal.pone.0112327 · Cited by 84
Sancho‐Martínez, S. M., Piedrafita, F. J., Cannata-Andía, J. B., López-Novoa, J. M., & López-Hernández, F. J. (2011) · Toxicological Sciences · doi:10.1093/toxsci/kfr098 · Cited by 81
Mercantepe, F., Mercantepe, T., Topçu, A., Yılmaz, A., & Tümkaya, L. (2018) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-018-1514-4 · Cited by 81
Srivastava, T., Sharma, M., Yew, K.-H., Sharma, R., Duncan, R. S., Saleem, M. A., McCarthy, E. T., Kats, A., Cudmore, P. A., Alon, U. S., et al. (2012) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-012-0184-0 · Cited by 80
Rabelo, L. A., Todiraş, M., Nunes-Souza, V., Qadri, F., Szijártó, I. A., Gollasch, M., Penninger, J. M., Bäder, M., Santos, R. A. S., & Alenina, N. V. (2016) · PLoS ONE · doi:10.1371/journal.pone.0150255 · Cited by 80
Gao, Z., Liu, G., Zhao, H., Li, X., Yang, X., Jiang, B., & Li, X. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.1883 · Cited by 79
TNF-α sensitizes chemotherapy and radiotherapy against breast cancer cells
Wu, X., Wu, M., Jiang, M., Zhi, Q., Bian, X., Xu, M., Gong, F.-R., Hou, J., Tao, M., Shou, L., et al. (2017) · Cancer Cell International · doi:10.1186/s12935-017-0382-1 · Cited by 77
Ma, Q., Xu, Y., Tang, L., Yang, X., Chen, Z., Wei, Y., Shao, X., Shao, X., Xin, Z., Cai, B., et al. (2020) · BioMed Research International · doi:10.1155/2020/2851349 · Cited by 75
Angiotensin (1-7) and Alamandine: Similarities and differences
Qaradakhi, T., Apostolopoulos, V., & Zulli, A. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.07.025 · Cited by 73
Self-citationPharmacologic recruitment of regulatory T cells as a therapy for ischemic acute kidney injury
Lai, L.-W., Yong, K.-C., & Lien, Y.-H. H. (2011) · Kidney International · doi:10.1038/ki.2011.412 · Cited by 72
Ni, J., Hou, X., Wang, X., Shi, Y., Xu, L., Zheng, X., Liu, N., Qiu, A., & Zhuang, S. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1589-y · Cited by 72
Coats, A. J. S., & Jain, S. (2017) · Journal of Human Hypertension · doi:10.1038/jhh.2017.8 · Cited by 71
Oxalate toxicity in renal cells
Jonassen, J. A., Kohjimoto, Y., Scheid, C. R., & Schmidt, M. R. (2005) · Urological Research · doi:10.1007/s00240-005-0485-3 · Cited by 68
Gillespie, S., Zhang, X. D., & Hersey, P. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1651.3.12 · Cited by 68
Chemotherapy for Bone Sarcoma in Adults
Wagner, M. J., Livingston, J. A., PATEL, S. R., & Benjamin, R. S. (2016) · Journal of Oncology Practice · doi:10.1200/jop.2015.009944 · Cited by 67
Fan, X., Wei, W., Huang, J., Liu, X., & Ci, X. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00264 · Cited by 67
Ebola Virus Glycoprotein Induces an Innate Immune Response In vivo via TLR4
Lai, C.-Y., Strange, D. P., Wong, T. A. S., Lehrer, A. T., & Verma, S. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.01571 · Cited by 66
Wen, X., Buckley, B., McCandlish, E. F., Goedken, M. J., Syed, S., Pelis, R. M., Manautou, J. E., & Aleksunes, L. M. (2014) · American Journal Of Pathology · doi:10.1016/j.ajpath.2014.01.025 · Cited by 64
Shahbazi, F., Sadighi, S., Dashti‐Khavidaki, S., Shahi, F., Mirzania, M., Abdollahi, A., & Ghahremani, M. (2015) · Phytotherapy Research · doi:10.1002/ptr.5345 · Cited by 63
Chemokine CXCL1 Dimer Is a Potent Agonist for the CXCR2 Receptor
Ravindran, A., Sawant, K. V., Sarmiento, J., Navarro, J., & Rajarathnam, K. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.443762 · Cited by 63
Galgamuwa, R., Hardy, K., Dahlstrom, J. E., Blackburn, A. C., Wium, E., Rooke, M., Cappello, J. Y., Tummala, P., Patel, H. R., Chuah, A., et al. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015070827 · Cited by 63
Toll-Like Receptor 4 Inhibitor TAK-242 Attenuates Acute Kidney Injury in Endotoxemic Sheep
Fenhammar, J., Rundgren, M., Forestier, J., Kalman, S., Eriksson, S., & Frithiof, R. (2011) · Anesthesiology · doi:10.1097/aln.0b013e31820b8b44 · Cited by 62
TLR2 and TLR4 play opposite role in autophagy associated with cisplatin-induced acute kidney injury
Andrade-Silva, M., Cenedeze, M. A., Perandini, L. A., Felizardo, R. J. F., Watanabe, I. K. M., Agudelo, J. S. H., Castoldi, Â., Gonçalves, G. M., Origassa, C. S. T., Semedo, P., et al. (2018) · Clinical Science · doi:10.1042/cs20170262 · Cited by 62
Zhang, Y., Chen, Y., Li, B., Ding, P., Jin, D., Hou, S., Cai, X., & Sheng, X. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110408 · Cited by 62
Toll-like receptor signaling regulates cisplatin-induced mechanical allodynia in mice
Park, H. J., Stokes, J. A., Corr, M., & Yaksh, T. L. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2304-9 · Cited by 61
Bridging translation for acute kidney injury with better preclinical modeling of human disease
Skrypnyk, N. I., Siskind, L. J., Faubel, S., & de Caestecker, M. P. (2016) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00552.2015 · Cited by 61
Kong, D., Li, Z., Gao, C., Shi, S., Wang, N., Huang, Z., Li, W., & Hao, L. (2012) · Journal of Nephrology · doi:10.5301/jn.5000177 · Cited by 60
Wang, S., Xie, J., Li, J., Liu, F., Wu, X., & Wang, Z. (2016) · PubMed · Cited by 60
Identification of OAT1/OAT3 as Contributors to Cisplatin Toxicity
Hu, S., Leblanc, A. F., Gibson, A., Hong, K., Kim, J., Janke, L. J., Li, L., Vasilyeva, A. N., Finkelstein, D., Sprowl, J. A., et al. (2017) · Clinical and Translational Science · doi:10.1111/cts.12480 · Cited by 60
Toll-like receptor 4 is activated by platinum and contributes to cisplatin-induced ototoxicity
Babolmorad, G., Latif, A., Pollock, N. M., Domingo, I. K., Delyea, C., Rieger, A. M., Allison, W. T., & Bhavsar, A. P. (2021) · EMBO Reports · doi:10.15252/embr.202051280 · Cited by 60
Cited by
Pyroptosis in health and disease: mechanisms, regulation and clinical perspective
Liu, Y., Pan, R., Ouyang, Y., Gu, W., Xiao, T., Yang, H., Tang, L., Wang, H., Xiang, B., & Chen, P. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01958-2 · Cited by 337
Metadata
- Authors
- McSweeney, K. R., Gadanec, L. K., Qaradakhi, T., Ali, B. A., Zulli, A., & Apostolopoulos, V.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2021-03-29
- Volume
- 13
- Issue
- 7
- Pages
- 1572
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W3150252631
- Cited by
- 363
- References
- 271
- FWCI
- 32.10
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.